Isabelle Jeanclaude-Etter

This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 4 EPO patents. Top assignees: Bionomics Inc., Merck Patent Gmbh, Merck Serono S. a.. Active years: 2008-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Isabelle Jeanclaude-Etter. Retrieved from https://idiyas.com/inventor/isabelle-jeanclaude-etter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 2)

% Patents Active = 33.3

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 7.7

ph-index = 1

Forward Citations = 22(Granted Patents)

Company Filing History:

Laboratoires Serono S.a.

patents

where one patent can have more than one assignee

Years Active: 2008-2018

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9914702 - Amine derivatives as potassium channel blockers (2018-03-13),

2. 9493451 - Amine derivatives as potassium channel blockers (2016-11-15),

3. 9073940 - Tricyclic pyrazol amine derivatives (2015-07-07),

4. 8614215 - Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) (2013-12-24),

5. 7838522 - Benzothiazole formulations and use thereof (2010-11-23),

6. 7465736 - Azole methylidene cyanide derivatives and their use as protein kinase modulators (2008-12-16),

Title: The Innovations of Isabelle Jeanclaude-Etter

Introduction

Isabelle Jeanclaude-Etter is a prominent inventor based in Bellevue, Switzerland. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that modulate potassium channel activity. With a total of six patents to her name, her work has the potential to impact the treatment of various autoimmune and inflammatory diseases.

Latest Patents

One of her latest patents focuses on amine derivatives as potassium channel blockers. This invention relates to compounds that are useful in modulating potassium channel activity in cells, specifically targeting the Kv1.3 channels found in T cells. The invention also encompasses the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis. Additionally, it includes pharmaceutical compositions containing these compounds and methods for their preparation.

Career Highlights

Throughout her career, Isabelle has worked with notable companies such as Bionomics Inc. and Merck Patent GmbH. Her experience in these organizations has allowed her to refine her expertise in pharmaceutical development and patenting.

Collaborations

Isabelle has collaborated with several professionals in her field, including Pascale Gaillard and Jean-Pierre Gotteland. These collaborations have contributed to her innovative research and development efforts.

Conclusion

Isabelle Jeanclaude-Etter's work exemplifies the intersection of innovation and healthcare. Her contributions to potassium channel modulation hold promise for advancing treatments for autoimmune diseases.

Profile summary based on public USPTO records.